Hepatitis Screening in Community Pharmacies as a Measure of Reducing the Rate of Infections

  • Pallav Dave Regulatory Compliance Analyst, Louisville, KY,40223, USA


The burden of dealing with HBV and HCV still remain despite the progress that has been made in screening, vaccination, and treating the infections. On average, there about 354 million cases of hepatitis globally. Hepatitis has high mortality rates. On average, 1.1 million people lose their lives to the infections each year. Addressing hepatitis requires rigorous measures one of them being increasing screening. Hepatitis infections are identified through screening. As such, screening and taking the right preventative and treatment measures can help to reduce the risk of infections. However, screening is still a challenge. The number of people who screen for hepatitis remains low despite the efforts that have been put in place to increase uptake. The uptake of screening is low because of inadequate access to screening centers. Thus, increasing screening settings can help to increase uptake. Community pharmacies can help to bridge this barrier by making screening more accessible. They are accessible and in close proximity to vulnerable populations, which makes them ideal as screening settings. This review explores the potential of community pharmacies as screening settings for HBV and HCV and whether they can help to reduce the rate of infections.

Keywords: screening, hepatitis B, hepatitis C, community pharmacies

Keywords: screening, hepatitis B, hepatitis C, community pharmacies


Download data is not yet available.

Author Biography

Pallav Dave, Regulatory Compliance Analyst, Louisville, KY,40223, USA

Regulatory Compliance Analyst, Louisville, KY,40223, USA


1. World Health Organization. Global progress report on HIV, viral hepatitis and sexually transmitted infections: Accountability for the global health sector strategies 2016-2021: actions for impact.2021. Accessed March 7 2024. https://www.globalhep.org/sites/default/files/content/resource/files/2021-05/WHO%20Progress%20Report%202021.pdf
2. US Department of Health and Human Services. Viral hepatitis in the United States: data and trends. 2016. Accessed March 7 2024. https://www.hhs.gov/hepatitis/learn-about-viral-hepatitis/data-and-trends/index.html#2
3. Edlin BR, Eckhardt BJ, Shu MA, Holmberg SD, Swan T. Toward a more accurate estimate of the prevalence of hepatitis C in the United States. Hepatology. 2015;62(5):1353-63. https://doi.org/10.1002/hep.27978 PMid:26171595 PMCid:PMC4751870
4. Conners EE, Panagiotakopoulos L, Hofmeister MG, et al. Screening and testing for hepatitis B virus infection: CDC recommendations-United States, 2023. MMWR Recommendations and Reports. 2023;72(1):1. https://doi.org/10.15585/mmwr.rr7201a1
5. Lingala S, Ghany MG. Hepatitis B: screening, awareness, and the need to treat. Federal Practitioner. 2016; 33(Suppl 3):19S.
6. World Health Organization. Hepatitis C: key facts. 2023. Accessed 7 March 2024. https://www.who.int/news-room/fact-sheets/detail/hepatitis-c#:~:text=Early%20diagnosis%20can%20prevent%20health,at%20increased%20risk%20of%20infection .
7. Hayes MJ, Beavon E, Traeger MW, Dillon JF, Radley A, Nielsen S, Byrne CJ, Richmond J, Higgs P, Hellard ME, Doyle JS. Viral hepatitis testing and treatment in community pharmacies: a systematic review and meta-analysis. eClinicalMedicine. 2024;69. https://doi.org/10.1016/j.eclinm.2024.102489 PMid:38440399 PMCid:PMC10909633
8. Radley A, Robinson E, Aspinall EJ, Angus K, Tan L, Dillon JF. A systematic review and meta-analysis of community and primary-care-based hepatitis C testing and treatment services that employ direct acting antiviral drug treatments. BMC Health Services Research. 2019;19(1):1-3. https://doi.org/10.1186/s12913-019-4635-7 PMid:31660966 PMCid:PMC6819346
9. Centers for Disease Control and Prevention. Hepatitis B surveillance 2021. 2023. Accessed 7 March 2024. https://www.cdc.gov/hepatitis/statistics/2021surveillance/hepatitis-b.htm
10. Centers for Disease Control and Prevention. 2023 viral Hepatitis national progress report. 2023. Accessed 7 March 2024. https://www.cdc.gov/hepatitis/policy/npr/2023/index.htm
11. Centers for Disease Control and Prevention. Hepatitis C surveillance 2021. 2023. Accessed 7 March 2024. https://www.cdc.gov/hepatitis/statistics/2021surveillance/hepatitis-c.htm
12. Freeland C, Bodor S, Perera U, Cohen C. Barriers to hepatitis B screening and prevention for African immigrant populations in the United States: A qualitative study. Viruses. 2020;12(3):305. https://doi.org/10.3390/v12030305 PMid:32168926 PMCid:PMC7150884
13. US Department of Health and Human Services. Hepatitis B basic information. 2023. Accessed 7 March 2024. https://www.hhs.gov/hepatitis/learn-about-viral-hepatitis/hepatitis-b-basics/index.html
14. Shafiq M, Nadeem M, Sattar Z, et al. Identification of risk factors for hepatitis B and C in Peshawar, Pakistan. HIV/AIDS-Research and Palliative Care. 2015;7:223-31. https://doi.org/10.2147/HIV.S67429 PMid:26316823 PMCid:PMC4544815
15. Baha W, Foullous A, Dersi N, et al. Prevalence and risk factors of hepatitis B and C virus infections among the general population and blood donors in Morocco. BMC Public Health. 2013;13:1-8. https://doi.org/10.1186/1471-2458-13-50 PMid:23331910 PMCid:PMC3640941
16. Zibbell JE, Asher AK, Patel RC, et al. Increases in acute hepatitis C virus infection related to a growing opioid epidemic and associated injection drug use, United States, 2004 to 2014. American Journal of Public Health. 2018;108(2):175-81. https://doi.org/10.2105/AJPH.2017.304132 PMid:29267061 PMCid:PMC5846578
17. Aghaei AM, Gholami J, Sangchooli A, et al. Prevalence of injecting drug use and HIV, hepatitis B, and hepatitis C in people who inject drugs in the Eastern Mediterranean region: a systematic review and meta-analysis. The Lancet Global Health. 2023;11(8):e1225-37. https://doi.org/10.1016/S2214-109X(23)00267-X PMid:37474230
18. Scheibe A, Young K, Moses L, et al. Understanding hepatitis B, hepatitis C and HIV among people who inject drugs in South Africa: findings from a three-city cross-sectional survey. Harm Reduction Journal. 2019;16(1):1-1. https://doi.org/10.1186/s12954-019-0298-2 PMid:30975139 PMCid:PMC6460775
19. National Institute on Drug Abuse. Viral hepatitis. Accessed 7 March 2024. https://nida.nih.gov/research-topics/viral-hepatitis#References
20. Centers for Disease Prevention and Control. Viral hepatitis: general surveillance. 2024. Accessed 7 March 2024. https://www.cdc.gov/hepatitis/statistics/surveillanceguidance/GeneralSurveillance.htm
21. Jafari N, Farajzadegan Z, Ataei B. Surveillance system for hepatitis C infection: A practical approach. International Journal of Preventive Medicine. 2012 Mar;3(Suppl1):S48.
22. Krist AH, Davidson KW, Mangione CM, et al. Screening for hepatitis B virus infection in adolescents and adults: US Preventive Services Task Force recommendation statement. JAMA. 2020;324(23):2415-22. https://doi.org/10.1001/jama.2020.22980 PMid:33320230
23. Abara WE, Qaseem A, Schillie S, et al. Hepatitis B vaccination, screening, and linkage to care: best practice advice from the American College of Physicians and the Centers for Disease Control and Prevention. Annals of Internal Medicine. 2017;167(11):794-804. https://doi.org/10.7326/M17-1106 PMid:29159414
24. Owens DK, Davidson KW, Krist AH, et al. Screening for hepatitis C virus infection in adolescents and adults: US Preventive Services Task Force recommendation statement. JAMA. 2020 Mar 10;323(10):970-5. https://doi.org/10.1001/jama.2020.1123 PMid:32119076
25. Toy M, Hutton D, Harris AM, Nelson N, Salomon JA, So S. Cost-effectiveness of 1-time universal screening for chronic hepatitis B infection in adults in the United States. Clinical Infectious Diseases. 2022;74(2):210-7. https://doi.org/10.1093/cid/ciab405 PMid:33956937
26. Schillie S, Wester C, Osborne M, Wesolowski L, Ryerson AB. CDC recommendations for hepatitis C screening among adults-United States, 2020. MMWR Recommendations and Reports. 2020;69(2):1. https://doi.org/10.15585/mmwr.rr6902a1
27. Strand MA, Bratberg J, Eukel H, Hardy M, Williams C. Peer reviewed: community pharmacists' contributions to disease management during the COVID-19 pandemic. Preventing Chronic Disease. 2020;17:E69. https://doi.org/10.5888/pcd17.200317 PMid:32701431 PMCid:PMC7380294
28. Gubbins PO, Klepser ME, Dering-Anderson AM, et al. Point-of-care testing for infectious diseases: opportunities, barriers, and considerations in community pharmacy. Journal of the American Pharmacists Association. 2014;54(2):163-71. https://doi.org/10.1331/JAPhA.2014.13167 PMid:24632931
29. Larkins MC, Thombare A. Point-of-Care testing. InStatPearls [Internet] 2023 May 29. StatPearls Publishing.
30. Weidle PJ, Lecher S, Botts LW, et al. HIV testing in community pharmacies and retail clinics: a model to expand access to screening for HIV infection. Journal of the American Pharmacists Association. 2014;54(5):486-92. https://doi.org/10.1331/JAPhA.2014.14045 PMid:25216878 PMCid:PMC4698873
31. Weber NC, Klepser ME, Akers JM, Klepser DG, Adams AJ. Use of CLIA-waived point-of-care tests for infectious diseases in community pharmacies in the United States. Expert Review of Molecular Diagnostics. 2016;16(2):253-64. https://doi.org/10.1586/14737159.2015.1116388 PMid:26560318
32. Buss VH, Deeks LS, Shield A, Kosari S, Naunton M. Analytical quality and effectiveness of point-of-care testing in community pharmacies: a systematic literature review. Research in Social and Administrative Pharmacy. 2019;15(5):483-95. https://doi.org/10.1016/j.sapharm.2018.07.013 PMid:30057328
33. Dong BJ, Lopez M, Cocohoba J. Pharmacists performing hepatitis C antibody point-of-care screening in a community pharmacy: A pilot project. Journal of the American Pharmacists Association. 2017;57(4):510-5. https://doi.org/10.1016/j.japh.2017.04.463 PMid:28602784
34. Buchanan R, Cooper K, Grellier L, Khakoo SI, Parkes J. The testing of people with any risk factor for hepatitis C in community pharmacies is cost‐effective. Journal of Viral Hepatitis. 2020;27(1):36-44. https://doi.org/10.1111/jvh.13207 PMid:31520434
35. Kugelmas M, Pedicone LD, Lio I, Simon S, Pietrandoni G. Hepatitis C point-of-care screening in retail pharmacies in the United States. Gastroenterology & Hepatology. 2017;13(2):98.
36. Brewer A, Hanna C, Eckmann L, Schadler A, Divine H. Patient awareness, willingness, and barriers to point-of-care hepatitis C screening in community pharmacy. Journal of the American Pharmacists Association. 2018;58(4):S69-72. https://doi.org/10.1016/j.japh.2018.04.031 PMid:30006188
37. Figueira I, Teixeira I, Rodrigues AT, Gama A, Dias S. Point-of-care HIV and hepatitis screening in community pharmacies: a quantitative and qualitative study. International Journal of Clinical Pharmacy. 2022;44(5):1158-68. https://doi.org/10.1007/s11096-022-01444-1 PMid:36098836 PMCid:PMC9469055
38. Isho NY, Kachlic MD, Marcelo JC, Martin MT. Pharmacist-initiated hepatitis C virus screening in a community pharmacy to increase awareness and link to care at the medical center. Journal of the American Pharmacists Association. 2017;57(3):S259-64. https://doi.org/10.1016/j.japh.2017.03.006 PMid:28506379
39. Kherghehpoush S, McKeirnan KC. Pharmacist-led HIV and hepatitis C point-of-care testing and risk mitigation counseling in individuals experiencing homelessness. Exploratory Research in Clinical and Social Pharmacy. 2021;1:100007. https://doi.org/10.1016/j.rcsop.2021.100007 PMid:35479505 PMCid:PMC9031368
40. Shah HA, Abu-Amara M. Education provides significant benefits to patients with hepatitis B virus or hepatitis C virus infection: a systematic review. Clinical Gastroenterology and Hepatology. 2013;11(8):922-33. https://doi.org/10.1016/j.cgh.2013.04.024 PMid:23639601
41. Surjadi M, Torruellas C, Ayala C, Yee HF, Khalili M. Formal patient education improves patient knowledge of hepatitis C in vulnerable populations. Digestive Diseases and Sciences. 2011;56:213-9. https://doi.org/10.1007/s10620-010-1455-3 PMid:20972850 PMCid:PMC3008930
42. Wong RJ, Khalili M. A patient-centered hepatitis B virus (HBV) educational intervention improves HBV care among underserved safety-net populations. Journal of Clinical Gastroenterology. 2020;54(7):642. https://doi.org/10.1097/MCG.0000000000001276 PMid:31688365 PMCid:PMC7744280
43. He T, Li K, Roberts MS, Spaulding AC, Ayer T, Grefenstette JJ, Chhatwal J. Prevention of hepatitis C by screening and treatment in US prisons. Annals of Internal Medicine. 2016;164(2):84-92. https://doi.org/10.7326/M15-0617 PMid:26595252 PMCid:PMC4854298
44. Durham DP, Skrip LA, Bruce RD, Vilarinho S, Elbasha EH, Galvani AP, Townsend JP. The impact of enhanced screening and treatment on hepatitis C in the United States. Clinical Infectious Diseases. 2016;62(3):298-304. https://doi.org/10.1093/cid/civ894 PMid:26628566 PMCid:PMC4706637
45. Heffernan A, Cooke GS, Nayagam S, Thursz M, Hallett TB. Scaling up prevention and treatment towards the elimination of hepatitis C: a global mathematical model. The Lancet. 2019;393(10178):1319-29. https://doi.org/10.1016/S0140-6736(18)32277-3 PMid:30704789
46. Zhou J, Wang FD, Li LQ, Chen EQ. Management of in-and out-of-hospital screening for hepatitis C. Frontiers in Public Health. 2023;10:984810. https://doi.org/10.3389/fpubh.2022.984810 PMid:36761331 PMCid:PMC9905736
47. Eckman MH, Ward JW, Sherman KE. Cost effectiveness of universal screening for hepatitis C virus infection in the era of direct-acting, pangenotypic treatment regimens. Clinical Gastroenterology and Hepatology. 2019;17(5):930-9. https://doi.org/10.1016/j.cgh.2018.08.080 PMid:30201597
48. Jones L, Atkinson A, Bates G, et al. Views and experiences of hepatitis C testing and diagnosis among people who inject drugs: systematic review of qualitative research. International Journal of Drug Policy. 2014;25(2):204-11. https://doi.org/10.1016/j.drugpo.2013.11.004 PMid:24332457
49. Stämpfli D, Imfeld-Isenegger TL, Hersberger KE, Messerli M. Hepatitis C virus screening in community pharmacies: results on feasibility from a Swiss pilot. BMC Infectious Diseases. 2023;23(1):1-0. https://doi.org/10.1186/s12879-023-08362-1 PMid:37286975 PMCid:PMC10246867
50. Selfridge M, Barnett T, Lundgren K, Guarasci K, Drost A, Fraser C. 'I just never wanted them to feel uncomfortable'-Barriers to pharmacy-based identification and treatment of hepatitis C in Victoria, Canada. Canadian Liver Journal. 2024:e2023016. https://doi.org/10.3138/canlivj-2023-0016
51. Yoo GJ, Fang T, Zola J, Dariotis WM. Destigmatizing hepatitis B in the Asian American community: lessons learned from the San Francisco Hep B Free Campaign. Journal of Cancer Education. 2012;27:138-44. https://doi.org/10.1007/s13187-011-0252-9 PMid:21748476 PMCid:PMC4537654
99 Views | 5 Downloads
How to Cite
Dave P. Hepatitis Screening in Community Pharmacies as a Measure of Reducing the Rate of Infections. JDDT [Internet]. 15Mar.2024 [cited 19Apr.2024];14(3):234-9. Available from: https://jddtonline.info/index.php/jddt/article/view/6478